• Molecular NamePioglitazone
  • SynonymPioglitazona [INN-Spanish]; Pioglitazone [Ban:Inn]; pioglitazone HCl; Pioglitazone Hydrochloride; Pioglitazonum [INN-Latin]
  • Weight370.473
  • Drugbank_IDDB01132
  • ACS_NO111025-46-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.2
  • pkaN/A
  • LogD (pH=7, predicted)3.19
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.02
  • LogSw (predicted, AB/LogsW2.0)0.47
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds8
  • TPSA93.59
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability83.0
  • Protein binding99.0
  • Volume of distribution (VD)0.63 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPioglitazone (P) is metabolized extensively by CYP2C8, CYP3A4, and other CYP isozymes. Two major metabolites (M-III and M-IV) accumulate in blood and contribute to the pharmacological effect.
  • Half life11 h
  • Excretionin bile
  • Urinary ExcretionNegligible
  • Clerance1.2 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A